Comment from Morris Kylie

I ran for Millcreek Township supervisor because I believe that policy change can make a real impact on people's health and well-being. That belief is what drives my public service, and it's why I'm writing in support of the FDA's proposed decision to exclude these ingredients from the 503B bulk list. While GLP-1s were once on the FDA’s shortage list, they no longer are, meaning that pharmacies generally should not be compounding GLP-1s. Yet this practice has continued, fueling a gray market of counterfeit products that are not FDA-approved and bypass rigorous safety review. While flashy advertisements make these drugs look like generics, mass compounding is only a temporary solution when the severity of a shortage outweighs the potential risks of compounded medications. What I find particularly concerning, especially as a family medicine doctor, is the way compounders are exploiting people's genuine health concerns and vulnerabilities. A 2024 Gallup poll revealed that 61% of women reported wanting to lose weight, an insecurity that social media has only amplified. Combining high medication costs with aggressive online marketing promising "affordable solutions" creates the perfect conditions for exploitation. Pushing untested medications is a direct threat to the equitable healthcare our communities deserve. The FDA's proposed decision is exactly the kind of policy intervention that protects people at scale. FDA-approved GLP-1s are increasingly accessible, and there is no clinical justification for mass compounding to continue. Finalizing this decision would ensure that the medications reaching patients are the ones that help, not harm, them.